Becton Dickinson & Co.

Becton Dickinson & Co.

BDX

Market Cap$64.55B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Becton Dickinson & Co.Becton Dickinson & Co.37.71.73%3%3.30.3

Earnings Call Q1 2025

February 6, 2025 - AI Summary

Strong Q1 Performance: BD reported a 9.6% revenue growth (3.9% organic) in Q1 of fiscal 2025, exceeding financial goals. Adjusted diluted EPS grew by 28% to $3.43. The company showed expansion in margins, with adjusted gross margin at 54.8% and operating margin at 23.6%, highlighting effective execution of its BD Excellence strategy.
Updated Fiscal 2025 Guidance: BD maintained its currency-neutral total and organic revenue growth guidance while adjusting its expected revenue range for FY 2025 to $21.7 billion to $21.9 billion. Adjusted EPS guidance was raised to $14.30 to $14.60, indicating a confidence boost from strong Q1 results despite headwinds from foreign exchange.
Separation of Biosciences and Diagnostics Solutions: BD announced its intention to separate its Biosciences and Diagnostic Solutions business, aiming to enhance strategic focus and drive value creation. The separation decision aligns with BD's longer-term strategy and is expected to unlock significant value for both entities in their respective markets.

Exclusive for Stockcircle Pro members

Sign upSign Up
$477.16

Current Fair Value

112.3% upside

Undervalued by 112.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$64.55 Billion
Enterprise Value$82.22 Billion
Dividend Yield$3.89 (1.73042704626334%)
Earnings per Share$5.88
Beta0.45
Outstanding Shares289,505,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio37.68
PEG13
Price to Sales3.26
Price to Book Ratio1.99
Enterprise Value to Revenue4.07
Enterprise Value to EBIT41.84
Enterprise Value to Net Income47
Total Debt to Enterprise0.22
Debt to Equity0.34

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Becton, Dickinson And Co.

72,000 employees
CEO: Thomas Polen

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...